NCT02507492

RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC) injection of RM-493, in subjects with POMC (propiomelanocortin) or other related rare genetic mutations, on body weight, metabolic function and blood pressure. Patients who respond during the initial 84 days of treatment can enter into long-term (2-year) extensions. The study drug (RM-493) will be administered in an unblinded fashion.

Conditions

• Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation

Interventions

Type	Name	Description
DRUG	RM-493

Timeline

• Start date: 2015-01-01
• Primary completion: 2018-01-01
• Completion: 2018-07-01
• First posted: 2015-07-24
• Last updated: 2016-02-22

Locations

1 site across 1 country: Germany